Literature DB >> 33399102

Identification and analysis of circRNA-miRNA-mRNA regulatory network in hepatocellular carcinoma.

Daxiang Zhou1, Ling Dong2, Lishan Yang3, Qiang Ma3, Feng Liu3, Yanjie Li1, Shu Xiong4.   

Abstract

This study was to identify important circRNA-miRNA-mRNA (ceRNAs) regulatory mechanisms in hepatocellular carcinoma (HCC). The circRNA dataset GSE97332 and miRNA dataset GSE57555 were used for analyses. Functional enrichment analysis for miRNA and target gene was conducted using cluster Profiler. Survival analysis was conducted through R package Survival. The ceRNAs and drug-gene interaction networks were constructed. The ceRNAs network contained five miRNAs including hsa-miR-25-3p, hsa-miR-3692-5p, hsa-miR-4270, hsa-miR-331-3p, and hsa-miR-125a-3p. Among the network, hsa-miR-25-3p targeted the most genes, hsa-miR-3692-5p and hsa-miR-4270 were targeted by more circRNAs than other miRNAs, hsa-circ-0034326 and hsa-circ-0011950 interacted with three miRNAs. Furthermore, target genes, including NRAS, ITGA5, SLC7A1, SEC14L2, SLC12A5, and SMAD2 were obtained in drug-gene interaction network. Survival analysis showed NRAS, ITGA5, SLC7A1, SEC14L2, SLC12A5, and SMAD2 were significantly associated with prognosis of HCC. NRAS, ITGA5, and SMAD2 were significantly enriched in proteoglycans in cancer. Moreover, hsa-circ-0034326 and hsa-circ-0011950 might function as ceRNAs to play key roles in HCC. Furthermore, miR-25-3p, miR-3692-5p, and miR-4270 might be significant for HCC development. NRAS, ITGA5, SEC14L2, SLC12A5, and SMAD2 might be prognostic factors for HCC patients via proteoglycans in cancer pathway. Taken together, the findings will provide novel insight into pathogenesis, selection of therapeutic targets and prognostic factors for HCC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33399102      PMCID: PMC8687197          DOI: 10.1049/iet-syb.2020.0061

Source DB:  PubMed          Journal:  IET Syst Biol        ISSN: 1751-8849            Impact factor:   1.615


  41 in total

1.  Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET.

Authors:  Weidong Jiang; Dacheng Wen; Lulu Gong; Yu Wang; Zefeng Liu; Fangying Yin
Journal:  Biochem Biophys Res Commun       Date:  2018-04-13       Impact factor: 3.575

2.  Five functional polymorphisms of B7/CD28 co-signaling molecules alter susceptibility to colorectal cancer.

Authors:  Dongjuan Wu; Rong Tang; Qinghua Qi; Xinru Zhou; Huan Zhou; Yong Mao; Rui Li; Cuiping Liu; Weipeng Wang; Dong Hua; Xueguang Zhang
Journal:  Cell Immunol       Date:  2014-12-06       Impact factor: 4.868

3.  cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells.

Authors:  Hui Fu; Yuchao He; Lisha Qi; Lu Chen; Yi Luo; Liwei Chen; Yongmei Li; Ning Zhang; Hua Guo
Journal:  Cancer Lett       Date:  2017-06-23       Impact factor: 8.679

4.  MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers.

Authors:  Mohammed Elhendawy; Enas A Abdul-Baki; Sherief Abd-Elsalam; Maha M Hagras; Abdul-Aziz Zidan; Amira Y Abdel-Naby; Mona Watny; Ibrahem Ali Elkabash; Mohamed Labib Salem; Mohamed Elshanshoury; Shaimaa Soliman; Said Abdou
Journal:  Mol Biol Rep       Date:  2020-05-19       Impact factor: 2.316

5.  miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.

Authors:  Daniela Cimino; Cristiano De Pittà; Francesca Orso; Matteo Zampini; Silvia Casara; Elisa Penna; Elena Quaglino; Marco Forni; Christian Damasco; Eva Pinatel; Riccardo Ponzone; Chiara Romualdi; Cathrin Brisken; Michele De Bortoli; Nicoletta Biglia; Paolo Provero; Gerolamo Lanfranchi; Daniela Taverna
Journal:  FASEB J       Date:  2012-12-11       Impact factor: 5.191

Review 6.  Hepatocellular carcinoma and hepatitis B surface protein.

Authors:  Yong-Wei Li; Feng-Cai Yang; Hui-Qiong Lu; Jiong-Shan Zhang
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

7.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

8.  Symptom management in hepatocellular carcinoma.

Authors:  Virginia Chih-Yi Sun; Linda Sarna
Journal:  Clin J Oncol Nurs       Date:  2008-10       Impact factor: 1.027

Review 9.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

Review 10.  Circular RNAs in cancer: opportunities and challenges in the field.

Authors:  L S Kristensen; T B Hansen; M T Venø; J Kjems
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

View more
  3 in total

1.  The circRNA circSIAE Inhibits Replication of Coxsackie Virus B3 by Targeting miR-331-3p and Thousand and One Amino-Acid Kinase 2.

Authors:  Qingru Yang; Yuhan Li; Yan Wang; Xiaorong Qiao; Tingjun Liu; Hua Wang; Hongxing Shen
Journal:  Front Cell Infect Microbiol       Date:  2022-01-24       Impact factor: 5.293

Review 2.  Function of Circular RNAs in Fish and Their Potential Application as Biomarkers.

Authors:  Golam Rbbani; Artem Nedoluzhko; Jorge Galindo-Villegas; Jorge M O Fernandes
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 3.  Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma.

Authors:  Rui Liao; Lei Liu; Jian Zhou; Xufu Wei; Ping Huang
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.